146 related articles for article (PubMed ID: 37641982)
1. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria.
Moñino-Romero S; Kolkhir P; Ohanyan T; Szépfalusi Z; Weller K; Metz M; Scheffel J; Maurer M; Altrichter S
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):167-174. PubMed ID: 37641982
[TBL] [Abstract][Full Text] [Related]
2. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
Kolkhir P; Laires PA; Salameh P; Asero R; Bizjak M; Košnik M; Dissemond J; van Doorn M; Hawro T; Kasperska-Zajac A; Zajac M; Kocatürk E; Peter J; Parisi CAS; Ritchie CA; Kulthanan K; Tuchinda P; Fomina D; Kovalkova E; Khoshkhui M; Kouzegaran S; Papapostolou N; Du-Thanh A; Kamegashira A; Meshkova R; Vitchuk A; Bauer A; Grattan C; Staubach P; Bouillet L; Giménez-Arnau AM; Maurer M; Weller K
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
[TBL] [Abstract][Full Text] [Related]
3. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
8. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
10. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
Cakmak ME; Yeğit OO; Öztop N
Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
[TBL] [Abstract][Full Text] [Related]
12. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
Can PK; Etikan P; Degirmentepe EN; Kocaturk E
Asian Pac J Allergy Immunol; 2024 Jun; 42(2):132-137. PubMed ID: 33638627
[TBL] [Abstract][Full Text] [Related]
13. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
Salman A; Demir G; Bekiroglu N
Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
17. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
Salman A; Ergun T; Gimenez-Arnau AM
J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
[No Abstract] [Full Text] [Related]
18. Omalizumab response correlates with reduced IFN-γ-, IL-10- and IL-31-secreting cells in chronic spontaneous urticaria.
Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2078-2085. PubMed ID: 31954076
[TBL] [Abstract][Full Text] [Related]
19. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
[TBL] [Abstract][Full Text] [Related]
20. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
Salman A; Comert E
J Cutan Med Surg; 2019; 23(5):496-500. PubMed ID: 31030540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
